Jane F Djung

US Patent:

6677337, Jan 13, 2004

Filed:

Mar 5, 2003

Appl. No.:

10/382060

Inventors:

Matthew John Laufersweiler - Morrow OH
Cynthia Monesa Crago Clark - Loveland OH
Michael Philip Clark - Loveland OH
Jane Far-Jine Djung - Mason OH
Biswanath De - Cincinnati OH
Michael George Natchus - Alpharetta GA

Assignee:

The Procter Gamble Company - Cincinnati OH

International Classification:

A61K 31513

US Classification:

5142358, 514274, 514275, 544122, 544123, 544317, 544331

Abstract:

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, or enantiomeric and diasteriomeric forms or pharmaceutically acceptable salts thereof, have the formula: wherein R is an ether or amino unit, R is substituted phenyl, each R and R unit is independently selected from the group consisting of: a) hydrogen; and b) substituted or unsubstituted C -C hydrocarbyl selected from the group consisting of: i) C -C linear, branched or cyclic alkyl; ii) C -C aryl; iii) C -C heterocyclic; iv) C -C heteroaryl.

US Patent:

6730668, May 4, 2004

Filed:

Sep 18, 2002

Appl. No.:

10/246214

Inventors:

Michael Philip Clark - Loveland OH
Matthew John Laufersweiler - Morrow OH
Jane Far-Jine Djung - Mason OH
Michael George Natchus - Alpharetta GA
Biswanath De - Cincinnati OH

Assignee:

The Procter Gamble Company - Cincinnati OH

International Classification:

C07D41314

US Classification:

51421706, 514218, 5142232, 5142288, 5142305, 514241, 51425202, 51425216, 51425505, 514274, 514275, 540601, 540553, 544 63, 544 96, 544 98, 544105, 544116, 544119, 544216, 544316, 544331, 546238, 546295, 546296

Abstract:

The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines; R is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; each R unit is independently selected from the group consisting of: a) hydrogen; b) â(CH ) O(CH ) R ; c) â(CH ) NR R ; d) â(CH ) CO R ; e) â(CH ) OCO R f) â(CH ) CON(R ) ; g) â(CH ) OCON(R ) ; h) two R units can be taken together to form a carbonyl unit; i) and mixtures thereof; R , R , R , and R are each independently hydrogen, C -C alkyl, and mixtures thereof; R and R can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R units can be take together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5, n is an index from 0 to 5; Z is O, S, NR , or NOR ; R is hydrogen or C -C alkyl.

US Patent:

6790846, Sep 14, 2004

Filed:

May 7, 2002

Appl. No.:

10/140541

Inventors:

Michael Philip Clark - Loveland OH
Jane Far-Jine Djung - Mason OH
Steven Karl Laughlin - Taylor Mill KY
Joshua Spector Tullis - Broomfield CO
Michael George Natchus - Alpharetta GA
Biswanath De - Cincinnati OH

Assignee:

The Procter Gamble Company - Cincinnati OH

International Classification:

C07D41304

US Classification:

5142315, 51425404, 514269, 514326, 514340, 5462721, 546209, 544111, 544367, 544315

Abstract:

Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohns disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiters syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.

US Patent:

6821971, Nov 23, 2004

Filed:

Sep 18, 2002

Appl. No.:

10/245927

Inventors:

Michael Philip Clark - Loveland OH
Matthew John Laufersweiler - Cincinnati OH
Jane Far-Jine Djung - Mason OH
Biswanath De - Cincinnati OH

Assignee:

The Procter Gamble Company - Cincinnati OH

International Classification:

C07D48704

US Classification:

5142358, 5142365, 514274, 514275, 544122, 544123, 544296, 544316, 544 31, 544332

Abstract:

The present invention relates to compound which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein R comprises ethers or amines; R is: a) substituted or unsubstituted aryl; or b) substituted or unsubstituted heteroaryl; R and R units are each independently hydrogen, ethers, amines, amides, carboxylates, or said units can form a double bond, a carbonyl, or R and R can be taken together to form a substituted or unsubstituted ring comprising from 4 to 8 atoms, said ring selected from the group consisting of: i) carbocyclic; ii) heterocyclic; iii) aryl; iv) heteroaryl; v) bicyclic; and vi) heterobicyclic.

US Patent:

6919346, Jul 19, 2005

Filed:

Dec 2, 2003

Appl. No.:

10/726111

Inventors:

Michael Philip Clark - Loveland OH, US
Jane Far-Jine Djung - Mason OH, US
Steven Karl Laughlin - Taylor Mill KY, US
Joshua Spector Tullis - Broomfield CO, US
Michael George Natchus - Alpharetta GA, US
Biswanath De - Cincinnati OH, US

Assignee:

The Procter & Gamble Company - Cincinnati OH

International Classification:

C07D413/04
A61K031/506
A61P009/04
A61P019/02

US Classification:

514256, 514269, 544315, 544317

Abstract:

Isoxazolone compounds having the generic structure: are used to treat disease associated with unwanted cytokine activity, including rheumatoid arthritis, osteoarthritis, diabetes, HIV/AIDS, inflammatory bowel disease, Crohn's disease, ulcerative colitis, congestive heart, hypertension, chronic obstructive pulmonary disease, septic shock syndrome, tuberculosis, adult respiratory distress, asthma, atherosclerosis, muscle degeneration, periodontal disease, cachexia, Reiter's syndrome, gout, acute synovitis, anorexia and bulimia nervosa fever, malaise, myalgia and headaches.

US Patent:

8158641, Apr 17, 2012

Filed:

Mar 26, 2009

Appl. No.:

12/411760

Inventors:

Jane Far-Jine Djung - Furlong PA, US
Adam Golebiowski - Madison CT, US
Jack A. Hunter - Loveland OH, US
Gary P. Schrum - Maineville OH, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim am Rhein

International Classification:

C07D 239/48
A61K 31/505
A61P 9/00

US Classification:

514275, 544323

Abstract:

The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors having the structure shown below:.

US Patent:

8354407, Jan 15, 2013

Filed:

May 14, 2009

Appl. No.:

12/465704

Inventors:

Jane Far-Jine Djung - Furlong PA, US
Adam Golebiowski - Madison CT, US
Jack A. Hunter - Loveland OH, US
Gary P. Schrum - Maineville OH, US

Assignee:

Boehringer Ingelheim International GmbH - Ingelheim am Rhein

International Classification:

C07D 239/48
C07D 413/06
C07D 413/14
A61K 31/505
A61K 31/5355
A61P 9/04

US Classification:

5142358, 514275, 544122, 544323

Abstract:

The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

US Patent:

20070293494, Dec 20, 2007

Filed:

Jun 13, 2007

Appl. No.:

11/762394

Inventors:

Jane Djung - Furlong PA, US
Adam Golebiowski - Madison CT, US
Jack Hunter - Loveland OH, US
Gary Shrum - Maineville OH, US

International Classification:

A61K 31/5377
A61K 31/506
C07D 413/02
C07D 403/02

US Classification:

514235500, 514252140, 514275000, 544122000, 544295000, 544324000

Abstract:

The present invention relates to 2-arylamino-4-(heterocyclic)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(heterocyclic)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.